ArticleScientific reports2024
Anti-inflammatory response to 1,8-Cineol and associated microbial communities in Otitis media patients.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Efficacy of a 445 nm wavelength laser in the surgical treatment of chronic otitis media.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Bacterial and fungal communities and network dynamics in Otitis media patients upon 1,8-Cineol treatment.NPJ systems biology and applications · 2026Article
- Targeting Neutrophil/Eosinophil Extracellular Traps by Aptamer-Functionalized Nanosheets to Overcome Recalcitrant Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Differential influence of 1,8-Cineol on distinct hypoxia-related immune alterations in human monocytes.Scientific reports · 2025Article
- Effects of Eucalyptus Essential Oil on Growth, Immunological Indicators, Disease Resistance, Intestinal Morphology and Gut Microbiota inMicroorganisms · 2025Article
- Gut microbial communities in chronic rhinosinusitis patients in response to 1,8-Cineol treatment.Current research in microbial sciences · 2025Article
- Chronic suppurative otitis media: disrupted host-microbial interactions and immune dysregulation.Frontiers in immunology · 2025Review
- Unveiling the hidden arsenal: new insights intoFrontiers in cellular and infection microbiology · 2024Review
- Dynamics of the Interleukin-10 Family of Cytokines in Chronic Otitis Media Patients upon 1,8-Cineol Treatment.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chronic Otitis Media (COM) is defined as long term inflammation and colonization with pathogenic bacteria due to a defect or retraction of the tympanic membrane. Surgical interventions are often augmented by antibiotic resistance development and therefore, off-label treatment using the natural drug 1,8-Cineol was carried out. All COM patients underwent antibiotic therapy and middle ear surgery and developed antibiotic resistances. Microbiological investigations from the auditory canal and stool samples were performed in correlation with the clinical course. Therapy of COM patients with 1,8-Cineol revealed a clear reduction of inflammatory microbes P. aeruginosa and Proteus mirabilis in ear samples as well as intestinal Prevotella copri, which was associated with an improved clinical outcome in certain individuals. The present off-label study revealed manifold anti-inflammatory effects of the natural monoterpene 1,8-Cineol in Otitis media patients. A better understanding of the underlying mechanisms will improve the current treatment options and possible forms of application of this natural drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.